How Much Does Trulicity Cost in Maine in 2026?

Trulicity Cash-Pay Price at Maine Pharmacies

The manufacturer list price for Trulicity set by Eli Lilly is $931 per month for a four-pen carton at any dose strength. Maine retail pharmacies charge roughly the same figure for patients paying without insurance, though individual pharmacy pricing can vary by $20 to $50 depending on location.

That number is consistent across dose tiers. Whether a prescriber starts a patient on the 0.75 mg initiation dose or titrates up to the maximum 4.5 mg dose, the per-carton price remains $931. This flat pricing structure differs from semaglutide products, where dose-dependent pricing creates more variability. For reference, the FDA-approved prescribing information lists four dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, all administered once weekly via prefilled autoinjector pen.

Patients filling at independent pharmacies in rural Maine counties (Aroostook, Piscataquis, Washington) sometimes face slightly higher prices due to limited competition and distribution costs. Chain pharmacies in the Portland, Bangor, and Lewiston-Auburn corridors tend to cluster closer to the $931 list price. Calling ahead to compare pricing between two or three pharmacies within driving distance can save $20 to $40 per fill.

Maine Medicaid Coverage for Trulicity

Maine Medicaid (MaineCare) covers Trulicity for adults with type 2 diabetes, but a prior authorization is required before the pharmacy can dispense it. The PA process typically takes 48 to 72 hours when the prescriber submits documentation showing the patient has tried and failed (or has a contraindication to) metformin as first-line therapy.

MaineCare's preferred drug list categorizes GLP-1 receptor agonists by clinical and cost criteria. Prescribers must document a diagnosis of type 2 diabetes, current A1C level, and prior medication trials. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line agents after metformin, and as first-line therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease. Citing these guidelines in the PA request strengthens approval odds.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced major adverse cardiovascular events (MACE) by 12% compared to placebo over a median follow-up of 5.4 years (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) in adults with type 2 diabetes who had cardiovascular risk factors or established CVD [1]. This cardiovascular outcome data is particularly relevant for PA requests involving patients with existing heart disease, as it provides the clinical rationale MaineCare reviewers look for when approving coverage.

For patients who receive a PA denial, Maine law requires Medicaid to provide a written explanation and an appeals process. Most denials result from incomplete documentation rather than clinical ineligibility. Resubmission with chart notes showing A1C values, body weight, and a clear treatment history resolves the majority of initial denials within two weeks.

Commercial Insurance Coverage in Maine

Most commercial insurance plans sold in Maine (Anthem, Aetna, Cigna, Harvard Pilgrim/Point32Health, and plans on the ACA marketplace) include Trulicity on their formularies, though tier placement varies. Trulicity typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays ranging from $50 to $150 per month for patients with standard commercial coverage.

Plans that place Trulicity on Tier 4 often prefer a different GLP-1 agonist. Semaglutide (Ozempic) or liraglutide (Victoza) may be listed as the preferred option, requiring step therapy before Trulicity approval. In these cases, the prescriber can submit a formulary exception request documenting why dulaglutide is medically necessary. Common clinical reasons include injection frequency preference (once weekly vs. daily for liraglutide), prior adverse reaction to semaglutide, or the cardiovascular mortality benefit shown in REWIND.

Employer-sponsored plans, which cover the majority of commercially insured Maine residents, vary more widely. Large employers (Bath Iron Works, L.L.Bean, MaineHealth system employees) negotiate their own formularies through pharmacy benefit managers (PBMs). Patients should check their specific plan's formulary through their insurer's online portal or by calling the member services number on their insurance card. The plan's Summary of Benefits will list the specific copay or coinsurance for the tier where Trulicity falls.

Medicare Part D plans in Maine cover Trulicity for type 2 diabetes, but out-of-pocket costs depend on the plan's coverage phase. Under the Inflation Reduction Act provisions now fully in effect, annual out-of-pocket prescription costs for Medicare beneficiaries are capped at $2,000 per year. For a drug priced at $931 per month, a Medicare Part D enrollee will reach that cap within two to three months, after which the plan covers 100% of remaining costs for the calendar year.

The Eli Lilly Savings Card in Maine

Eli Lilly offers the Trulicity Savings Card for commercially insured patients. Eligible patients can pay as little as $25 per monthly fill, with the card covering the difference between the patient's copay and $25, up to a maximum annual benefit. The card is not available to patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded programs.

To activate the card, patients visit the Eli Lilly Trulicity website, confirm their insurance type, and receive a digital or physical savings card with a BIN, PCN, and group number. The pharmacist processes it as a secondary claim after the primary insurance adjudicates. Processing is automatic at most Maine chain pharmacies (CVS, Walgreens, Hannaford, Rite Aid). Independent pharmacies can also process the card but may need the BIN/PCN information entered manually.

The savings card has an annual maximum benefit, typically around $12,000 per year. Given the $931 list price, patients using the card at Tier 3 or Tier 4 copay levels will rarely approach this ceiling. The card resets each January. Patients must re-enroll annually, though Eli Lilly typically sends reminders to existing cardholders.

One limitation: patients in high-deductible health plans (HDHPs) may find the card less effective during their deductible phase. Some PBMs apply the savings card amount toward the deductible, while others do not. Patients should confirm with their PBM whether manufacturer copay assistance counts toward their deductible and out-of-pocket maximum, as this varies by plan design.

Compounded Dulaglutide in Maine

Compounded dulaglutide is available in Maine through licensed 503A compounding pharmacies. Under federal law, 503A pharmacies can compound medications based on a valid patient-specific prescription when a prescriber determines a clinical need, such as a non-standard dose or allergy to an inactive ingredient in the brand product.

Maine's Board of Pharmacy regulates 503A compounding pharmacies operating within the state. Out-of-state 503A pharmacies can ship compounded medications to Maine patients if they hold a non-resident pharmacy license from the Maine Board of Pharmacy. The FDA's guidance on compounding outlines the federal framework that governs these operations.

Several telehealth platforms now offer compounded GLP-1 receptor agonist prescriptions to Maine residents. Before choosing a compounded product, patients should verify that the compounding pharmacy is licensed, uses USP 797-compliant sterile compounding practices, and provides certificates of analysis (COA) for potency and sterility on each batch.

The clinical distinction matters. Brand Trulicity uses a proprietary autoinjector pen and has undergone the full FDA approval process, including the large-scale REWIND cardiovascular outcome trial [1]. Compounded dulaglutide has not undergone independent clinical trials and does not carry the same FDA-approved labeling. The active ingredient is the same molecule, but the delivery device, excipients, and quality assurance process differ.

Dr. Caroline Messer, an endocrinologist at Lenox Hill Hospital, has stated: "Patients considering compounded GLP-1 agonists should understand that while the active peptide may be identical, the manufacturing standards, stability testing, and device engineering of FDA-approved products provide a level of quality assurance that compounded products cannot replicate."

Telehealth Prescribing of Trulicity in Maine

Maine permits telehealth prescribing of Trulicity. A licensed prescriber (physician, nurse practitioner, or physician assistant with Maine licensure) can evaluate a patient via synchronous video or audio visit, diagnose type 2 diabetes or confirm an existing diagnosis, and prescribe dulaglutide without an in-person visit.

Maine adopted permanent telehealth parity legislation, requiring commercial insurers to reimburse telehealth visits at the same rate as in-person visits for the same service. MaineCare also covers telehealth visits for medication management, including GLP-1 prescribing.

Several national telehealth platforms operate in Maine and can prescribe brand Trulicity or compounded dulaglutide. Patients should confirm that the prescriber holds an active Maine medical license and that the platform's pharmacy partner can ship to Maine addresses. Most platforms handle the prior authorization process for commercially insured and Medicaid patients.

For patients in rural Maine, telehealth removes a significant barrier. The state has 16 counties, and endocrinology practices are concentrated in Cumberland (Portland) and Penobscot (Bangor) counties. Telehealth allows patients in Washington, Aroostook, or Somerset counties to access specialized metabolic care without multi-hour drives. According to the National Institutes of Health, telehealth adoption for chronic disease management has increased substantially since 2020, and rural states like Maine have seen disproportionate benefit.

How Trulicity Compares to Other GLP-1 Options on Cost in Maine

Trulicity's $931 monthly list price places it in a similar range to other branded GLP-1 receptor agonists. Ozempic (semaglutide) lists at roughly $935 to $1,029 per month depending on dose, while Mounjaro (tirzepatide), a dual GIP/GLP-1 agonist, lists at approximately $1,023 to $1,069 per month.

The clinical profiles differ. The SUSTAIN-7 trial directly compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide produced greater A1C reductions (1.5% vs. 1.1% at the lower doses; 1.8% vs. 1.4% at the higher doses) and greater weight loss (4.6 kg vs. 2.3 kg at the lower doses; 6.5 kg vs. 3.0 kg at the higher doses) [2].

The American Association of Clinical Endocrinology (AACE) 2023 consensus algorithm recommends GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and ASCVD. Both dulaglutide (REWIND) and semaglutide (SUSTAIN-6) have demonstrated cardiovascular risk reduction in large outcome trials. The choice between agents often depends on formulary placement, patient preference for injection device, and weight loss goals. As the Endocrine Society clinical practice guideline notes: "Selection among GLP-1 receptor agonists should consider cardiovascular and renal benefits, weight effects, cost, and patient preference."

For cost-conscious patients in Maine, the practical question is which GLP-1 agent their insurance prefers. Switching from a non-preferred agent to a preferred one within the same drug class can reduce monthly copays from $150 to $50 or less. The clinical differences, while statistically significant in head-to-head trials, may be secondary to the financial reality of long-term medication adherence.

Discount Programs and Patient Assistance Beyond the Savings Card

Beyond the Eli Lilly Savings Card, several additional options can reduce Trulicity costs for Maine patients. The Lilly Cares Patient Assistance Program provides free Trulicity to uninsured or underinsured patients who meet income eligibility requirements (generally at or below 400% of the federal poverty level). Applications require proof of income, a prescription, and a prescriber signature.

GoodRx, RxSaver, and similar prescription discount aggregators show cash-pay prices at Maine pharmacies and can sometimes reduce costs by $50 to $100 off the list price, though for a $931 drug the savings remain modest. These coupons cannot be combined with insurance or the Eli Lilly Savings Card.

Maine's Drugs for the Elderly and Disabled (DEL) program, administered by the Maine Department of Health and Human Services, helps qualifying residents aged 62 and older or those receiving Social Security disability benefits with prescription costs. Enrollment requires Maine residency and income below 185% of the federal poverty level. The program can supplement Medicare Part D coverage to reduce out-of-pocket costs for high-priced medications.

340B-eligible health centers, including Federally Qualified Health Centers (FQHCs) in Maine such as Penobscot Community Health Care and Greater Portland Health, can dispense medications at reduced 340B pricing to eligible patients. Patients receiving care at these centers should ask whether 340B pricing applies to their Trulicity prescription, as the discount can be substantial.

The annual out-of-pocket cost difference between full cash-pay ($11,172/year) and optimized coverage through insurance plus manufacturer assistance ($300 to $600/year) is significant enough that spending time on coverage optimization before filling the first prescription is clinically justified. Medication adherence for GLP-1 agonists drops sharply when monthly out-of-pocket costs exceed $50, according to data published in Diabetes Care.